ClinicalTrials.gg
Status unknownNCT03799575Updated Jan 10, 2019

Internal Limiting Membrane and Macular Hole

An observational study in C11.768.740, sponsored by Hospital de Santa Maria, Portugal. Status unknown at 1 site in Portugal. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-01-10.

Sponsored by Hospital de Santa Maria, Portugal · Observational

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Observational study of Internal Limiting Membrane peeled in macular Hole surgery and studied by Transmission electronic Microscopy (TEM) and Optical Coherence Tomography (OCT) findings in closed holes.

Read the detailed description

A non-randomized prospective study of eyes with MH willing to have surgery at the Department of Ophthalmology of Santa Maria Hospital, Lisbon.

Surgeries are performed under local or general anesthesia, pars plana vitrectomy with internal limiting membrane peeling, fluid gas exchange and face down position.

Two samples of discarded ILM peeled in Macular hole surgery is studied in Laboratory.

Laboratory Analysis Two samples of ILM per patient are harvested, one will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis. Both samples from same patient will follow the protocol available at dx.doi.org/10.17504/protocols.io.qjiduke.

Image acquisition Six electron-micrographs will be acquired for each fragment, using a Hitachi H-7000 electron microscope equipped with a megaview III digital camera. Fields of interest will be randomly selected, and acquisition of 15,000x magnification images.

Histology and immunohistochemistry ILM samples will be stained with anti-GFAP antibody (anti-glial fibrillary acidic protein), to detect this protein in glial cells.

Results:

Only successful macular hole closure will be considered, BCVA will be compared before and after surgery and related to OCT findings. ILM findings in TEM analysis will be compared with and without enriched medium.

02

Conditions studied

  • C11.768.740
03

In context

Lead sponsor

Hospital de Santa Maria, Portugal is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A non-randomized prospective study of eyes with MH willing to have surgery at the Department of Ophthalmology of Santa Maria Hospital, Lisbon.

Inclusion criteria

  1. Full Thickness Macular Hole
  2. Male or female aged 18 years or older
  3. Visual symptoms due to IMH
  4. Intraocular pressure inferior to 21 mmHG
  5. Signed informed consent form

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All macular holes were staged based on recent OCT based classification and only full thickness macular hole, grade 2 to 4 IMH are considered for study.

Exclusion criteria

Exclusion Criteria:

  • Excluding criteria are maculopathy other than IMH, surgeries of recurrence of IMH, other retinal diseases, or an axial length greater than 26.0 mm. Mean follow-up will be at least 12 months after surgery.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • A

    Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.

    Behavioral: Transmission Electron Microscopy analysis

  • B

    Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.

    Behavioral: Transmission Electron Microscopy analysis

Interventions

  • BehavioralTransmission Electron Microscopy analysis

    Morphology of two vitreal side of Internal Limiting Membrane in contact

06

What researchers measure

Primary outcomes

  1. Fibrosis in vitreal sides of Internal Limiting Membranes

    Fibrilliary process between two vitreal sides of Internal Limiting Membranes in contact, after incubation in enriched medium

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Santa Maria
    Lisbon, Lisboa 1649-035, Portugal
    Recruiting
08

References and documents

Publications

  • Faria MY, Sousa DC, Almeida BC, Pinto AL, Ferreira NP. Morphology of Peeled Internal Limiting Membrane in Macular Hole Surgery. J Ophthalmol. 2019 May 2;2019:1345683. doi: 10.1155/2019/1345683. eCollection 2019. PubMed 31191990 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03799575
Lead sponsor
Hospital de Santa Maria, Portugal
Responsible party
Mun Yueh de Faria (MD, Hospital de Santa Maria, Portugal) — Principal investigator
First posted
Jan 10, 2019
Start date
Jan 2, 2019
Primary completion
Jul 2, 2019 (estimated)
Completion
Jul 2, 2019 (estimated)
Last update
Jan 10, 2019

Study contacts

Nuno P Ferreira, MD
Contact
ngcpferreira@gmail.com
+351918503467
Andreia L Pinto, MSC
Contact
andreia.lucia.pinto@gmail.com
+351969721099
Mun Y Faria, MD
principal investigator · Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, 1649-035 Lisboa, PT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion